Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis

Authors DiSantostefano RL, Li H, Hinds D, Galkin DV, Rubin DB

Received 11 January 2014

Accepted for publication 10 March 2014

Published 7 May 2014 Volume 2014:9(1) Pages 457—468

DOI https://doi.org/10.2147/COPD.S60498

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Rachael L DiSantostefano,1 Hao Li,1 David Hinds,1 Dmitry V Galkin,2 David B Rubin2

1Worldwide Epidemiology, 2Respiratory Clinical Development, GlaxoSmithKline, Research Triangle Park, Durham, NC, USA

Background: Pneumonia poses a significant risk in patients with moderate to severe chronic obstructive pulmonary disease but data are limited on the disease phenotypes most susceptible to pneumonia.
Methods: Cluster analysis using a data-driven recursive partitioning algorithm was employed using baseline data from two pooled one-year randomized exacerbation trials (n=3,255) of fluticasone furoate/vilanterol or vilanterol alone to identify distinct patient groups at greatest risk of pneumonia or serious (hospitalization or death) pneumonia.
Results: Five clusters were identified. Patients at greater risk of first pneumonia had more severe obstruction (forced expiratory volume in one second/forced vital capacity <46%) and either a body mass index <19 kg/m2 (hazard ratio 7.8, 95% confidence interval 4.7–13.0; n=144) or a pneumonia history and greater comorbidities (hazard ratio 4.8, 95% confidence interval 3.0–7.7; n=374) relative to the cluster with the lowest pneumonia risk (reference; n=1310). Multiple comorbidities and use of psychoanaleptics also contributed to an increased risk of pneumonia in more obstructed patients. Independent of cluster, use of inhaled corticosteroids was associated with pneumonia (hazard ratio 1.89, 95% confidence interval 1.25–2.84) and serious pneumonia (hazard ratio 2.92, 95% confidence interval 1.40–6.01).
Conclusion: Cluster analysis can identify patient populations at risk for serious safety outcomes and inform risk management strategies to optimize patient management. The greatest risk for pneumonia was in subjects with multiple pneumonia risk factors.

Keywords: chronic obstructive pulmonary disease, inhaled corticosteroids, long-acting β2-agonists, pneumonia, cluster analysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Today's diverse nano-theranostic applications and tomorrow's promises

Webster TJ, Lee S, An SSA

International Journal of Nanomedicine 2015, 10:1-2

Published Date: 25 August 2015

The prevalence of obstructive sleep apnea-hypopnea syndrome-related symptoms and their relation to airflow limitation in an elderly population receiving home care

Kleisiaris CF, Kritsotakis EI, Daniil Z, Tzanakis N, Papaioannou A, Gourgoulianis KI

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1111-1117

Published Date: 10 October 2014

The mediating role of cytokine IL-6 on the relationship of FEV1 upon 6-minute walk distance in chronic obstructive pulmonary disease

Baldi S, Jose PE, Bruschi C, Pinna GD, Maestri R, Rezzani A, Bellinzona E, Fracchia C, Dacosto E, Crotti P, Montemartini S

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1091-1099

Published Date: 7 October 2014

Adjunctive treatment with oral AKL1, a botanical nutraceutical, in chronic obstructive pulmonary disease

Brockwell C, Ampikaipakan S, Sexton DW, Price D, Freeman D, Thomas M, Ali M, Wilson AM

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:715-721

Published Date: 9 July 2014

The successful treatment of hypercapnic respiratory failure with oral modafinil

Parnell H, Quirke G, Farmer S, Adeyemo S, Varney V

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:413-419

Published Date: 30 April 2014